Vanda Pharmaceuticals Inc (VNDA)
4.94
+0.04
(+0.82%)
USD |
NASDAQ |
Nov 21, 16:00
4.935
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Enterprise Value: -88.22M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -88.22M |
| November 20, 2024 | -90.55M |
| November 19, 2024 | -89.39M |
| November 18, 2024 | -85.89M |
| November 15, 2024 | -84.72M |
| November 14, 2024 | -78.89M |
| November 13, 2024 | -57.90M |
| November 12, 2024 | -61.40M |
| November 11, 2024 | -64.90M |
| November 08, 2024 | -73.64M |
| November 07, 2024 | -83.55M |
| November 06, 2024 | -91.13M |
| November 05, 2024 | -96.97M |
| November 04, 2024 | -93.47M |
| November 01, 2024 | -104.55M |
| October 31, 2024 | -105.13M |
| October 30, 2024 | -110.39M |
| October 29, 2024 | -102.81M |
| October 28, 2024 | -97.56M |
| October 25, 2024 | -110.97M |
| October 24, 2024 | -112.72M |
| October 23, 2024 | -102.81M |
| October 22, 2024 | -100.47M |
| October 21, 2024 | -100.47M |
| October 18, 2024 | -89.98M |
| Date | Value |
|---|---|
| October 17, 2024 | -100.18M |
| October 16, 2024 | -90.56M |
| October 15, 2024 | -96.39M |
| October 14, 2024 | -95.81M |
| October 11, 2024 | -117.38M |
| October 10, 2024 | -119.13M |
| October 09, 2024 | -115.63M |
| October 08, 2024 | -114.47M |
| October 07, 2024 | -113.88M |
| October 04, 2024 | -106.30M |
| October 03, 2024 | -113.88M |
| October 02, 2024 | -108.64M |
| October 01, 2024 | -111.55M |
| September 30, 2024 | -102.81M |
| September 27, 2024 | -115.46M |
| September 26, 2024 | -111.38M |
| September 25, 2024 | -104.97M |
| September 24, 2024 | -98.56M |
| September 23, 2024 | -110.80M |
| September 20, 2024 | -118.96M |
| September 19, 2024 | -116.63M |
| September 18, 2024 | -99.14M |
| September 17, 2024 | -99.72M |
| September 16, 2024 | -91.56M |
| September 13, 2024 | -90.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-295.40M
Minimum
Nov 09 2023
800.06M
Maximum
Jun 30 2021
171.97M
Average
163.61M
Median
Jun 28 2022
Enterprise Value Benchmarks
| Zevra Therapeutics Inc | 456.85M |
| Black Diamond Therapeutics Inc | 24.82M |
| Edgewise Therapeutics Inc | 2.536B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.324M |
| Revenue (Quarterly) | 47.65M |
| Total Expenses (Quarterly) | 58.65M |
| EPS Diluted (Quarterly) | -0.09 |
| Gross Profit Margin (Quarterly) | 94.65% |
| Profit Margin (Quarterly) | -11.17% |
| Earnings Yield | -5.67% |
| Normalized Earnings Yield | -5.668 |